Replies to post #227546 on Amarin Corp Plc (AMRN)

[cmm3rd]

Primary and secondary prevention patients as defined by the REDUCE-IT study can be summarized as,

Primary: Patients with diabetes and risk factors for cardiovascular disease (i.e. prevention of cardiovascular disease)

Secondary: Patients with cardiovascular disease (i.e. prevention of additional cardiovascular disease)

So, my hypothetical patient, who is 40 y/o male, with LDLc controlled by statin therapy, has trigs 140, and has a calcium score of 25 (which establishes CVD), and no history of MACE and no diabetes, would, for REDUCE-IT label discussions, be a secondary prevention patient (meaning prevention of additional CVD), rather than primary prevention (prevention of an initial MACE event? (Even though he doesn't fall into either Risk Category 1 or Category 2).

If that is so, I'm unsure everyone is using the terms uniformly.

I do understand, though, how ambiguity might have built into the discussion by the discussion points.